Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease

Abstract

CVD among people with the metabolic syndrome is explained by their excess of atherosclerosis and impaired fibrinolysis. Interventions to prevent atherosclerosis progression and improve fibrinolytic function require evaluation in this high-risk group.